Nuvation Bio (NUVB) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
UroGen Pharma (URGN) has outperformed Nuvation Bio (NUVB) over the past year, gaining 113.4% versus a gain of 33.1%. Over five years, URGN leads with a +117.3% price change compared with -49.1% for NUVB. UroGen Pharma is the larger company by market cap ($1.81 billion vs $1.74 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NUVB | URGN |
|---|---|---|
| Share price | $4.95 | $36.98 |
| Market cap | $1.74B | $1.81B |
| 1-day change | +1.85% | -9.14% |
| YTD return | -44.75% | +57.90% |
| 1-year return | +33.06% | +113.39% |
| 5-year return | -49.11% | +117.27% |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $-0.44 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.75 | $50.81 |
| 52-week low | $3.36 | $15.86 |
| Distance from 52-week high | -49.23% | -27.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +162.63% | +62.25% |
| Average volume | 5.65M | 827.16K |
| Shares outstanding | 350.12M | 48.88M |
| Employees | 305 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed NUVB by 80.3 percentage points over the past year.
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
NUVB vs URGN FAQ
Which is bigger, Nuvation Bio or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.81B compared with $1.74B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, NUVB or URGN?
URGN returned +113.39% over the past 12 months, compared with +33.06% for NUVB (price return, excluding dividends). Past performance does not predict future results.
Are Nuvation Bio and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.